A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone

LESSONS LEARNED: Patients with metastatic castration-resistant prostate cancer did not tolerate the combination of alisertib with abiraterone and prednisone. There was no clear signal indicating that adding alisertib might be beneficial for those patients progressing on abiraterone. BACKGROUND. We h...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jianqing, Patel, Sheel A., Sama, Ashwin R., Hoffman-Censits, Jean H., Kennedy, Brooke, Kilpatrick, Deborah, Ye, Zhong, Yang, Hushan, Mu, Zhaomei, Leiby, Benjamin, Lewis, Nancy, Cristofanilli, Massimo, Kelly, William Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189628/
https://www.ncbi.nlm.nih.gov/pubmed/28178640
http://dx.doi.org/10.1634/theoncologist.2016-0297

Ejemplares similares

Ejemplares similares